Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London.
The event, delivered in partnership with the Medical Cannabis Clinicians Society (MCCS), will focus on strengthening clinical understanding and confidence in prescribing cannabis-based products for medicinal use (CBPMs).
Focus on Integration, Safety and Evidence
The symposium will bring together clinicians, pharmacists, researchers and patient advocates to explore how CBPMs can be more effectively integrated into mainstream treatment pathways.
Key themes include NHS collaboration, prescribing frameworks, pharmacist safety protocols, emerging therapeutic indications and equitable patient access.
Sessions will cover evidence from UK clinics on the use of CBPMs for mental health conditions such as anxiety and obsessive-compulsive disorder (OCD), as well as for neurological and neurodegenerative conditions including dementia.
The event aims to promote data-driven, evidence-based practice while addressing the regulatory and operational barriers that continue to limit access within NHS settings.
Curaleaf Laboratories’ sponsorship forms part of its ongoing collaboration with the MCCS to deliver structured, credible education for healthcare professionals. The company has invested in training initiatives designed to support clinicians in safely and effectively integrating CBPMs into clinical practice.
Building Prescriber Confidence
The programme will examine current prescribing trends and variations in cl
inical practice across private and NHS settings. It will outline frameworks for good clinical governance, prescribing accountability and professional development, with sessions designed to provide practical tools and guidance for clinicians.
A dedicated workshop stream led by MCCS experts will run alongside the main programme, covering topics such as the endocannabinoid system, product formulations, clinical indications and safety considerations. These interactive sessions aim to equip healthcare professionals with foundational knowledge and confidence to engage with CBPM prescribing responsibly.
Advancing Real-World Evidence
Several sessions will explore the growing body of real-world data supporting the safety and efficacy of CBPMs. These discussions will assess how evidence from clinical practice can complement randomised controlled trials, and how regulators and policymakers can incorporate such data into future decision-making frameworks.
The event will also examine the evolving role of pharmacists in ensuring safe supply, patient counselling and ongoing treatment monitoring, as well as strategies to enhance communication and data sharing between NHS and private providers.
Jonathan Hodgson, CEO at Curaleaf Laboratories, commented: “Providing education has always been hugely important to us. In order for us as a medical community to adequately support patients, it is important that healthcare professionals (HCPs) are able to access much-needed education on cannabis-based medicines so they can help their patients through guiding access or prescribing directly.”
Mike Barnes, Chair of the MCCS, added: “Having the support of Curaleaf for this event is a welcome continuation of our work together, and further evidence of their commitment to helping deliver evidence-based cannabis education to healthcare professionals throughout the UK. Through our existing partnership, Curaleaf has enabled the MCCS to continue delivering our education and training programmes and the conference will allow us to build on this, benefiting clinicians and ultimately patients.”
Supporting Safe and Equitable Access
With more than 60,000 patients in the UK now receiving CBPM prescriptions, almost entirely through private clinics, the symposium will focus on how to enable more consistent, equitable access across healthcare systems. Industry observers estimate that as many as 500,000 patients could benefit from treatment if NHS access were expanded.
Curaleaf Laboratories, part of Curaleaf International and a subsidiary of Curaleaf Holdings Inc., operates one of the UK’s largest EU-GMP medical cannabis manufacturing facilities. The company’s involvement in the symposium reinforces its commitment to supporting safe, compliant and patient-centred approaches to expanding CBPM access in the UK.
Further details and registration information are available at www.cannabishealthsymposium.co.uk.
